Figures & data
Note: Copyright © 2011. Reproduced with permission from John Wiley and Sons. Shigematsu T; for Lanthanum Carbonate Research Group. Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysis. Ther Apher Dial. 2008;12(1):55–61.Citation12
Note: Reproduced from Shigematsu T, Kono T, Satoh K, et al. Phosphate overload accelerates vascular calcium deposition in end-stage renal disease patients. Nephrol Dial Transplant. 2003;18 Suppl 3:iii86–iii89,Citation14 with permission from Oxford University Press.
Note: Reproduced from Shigematsu T; Lanthanum Carbonate Research Group. Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia. Clin Nephrol. 2008;70(5):404–410,Citation15 with permission from Dustri-Verlag Dr Karl Feistle GmbH and Co KG.
Note: From ShigematsuCitation21 with permission from Springer Japan and the Japanese Society of Nephrology.
Note: Copyright © 2011. Reproduced with permission from John Wiley and Sons. Shigematsu T, Tokumoto A, Nakaoka A, Arisaka H. Effect of lanthanum carbonate treatment on bone in Japanese dialysis patients with hyperphosphatemia. Ther Apher Dial. 2011;15(2):176–184.Citation24
Note: Reproduced from Shigematsu T, Negi S; for the COLC Research Group. Combined therapy with lanthanum carbonate and calcium carbonate for hyperphosphatemia decreases serum FGF-23 level independently of calcium and PTH (COLC Study). Nephrol Dial Transplant. 2012;27(3):1050–1054,Citation32 with permission from Oxford Journals.